MEK7 Recombinant Rabbit Monoclonal Antibody [SD20-87]
cat.: ET1612-35
| Product Type: | Recombinant Rabbit monoclonal IgG, primary antibodies |
|---|---|
| Species reactivity: | Human, Mouse, Rat |
| Applications: | WB, IF-Cell, IF-Tissue, IHC-P, IP, FC |
| Clonality: | Monoclonal |
| Clone number: | SD20-87 |
| Form: | Liquid |
| Storage condition: | Shipped at 4℃. Store at +4℃ short term (1-2 weeks). Store at -20℃ long term. |
| Storage buffer: | 1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1ug/ul |
| Purification: | Protein A affinity purified. |
| Molecular weight: | Predicted band size: 47 kDa |
| Isotype: | IgG |
| Immunogen: | Synthetic peptide within Human MEK7 aa 370-419 / 419. |
| Positive control: | HeLa, 293T, A431, Caco-2,A549, rat brain tissue, rat bladder tissue, mouse bladder tissue. |
| Subcellular location: | Nucleus, Cytoplasm. |
| Recommended Dilutions:
WB IF-Cell IF-Tissue IHC-P FC |
1:1,000-1:2,000 1:50-1:200 1:50-1:200 1:50-1:200 1:50-1:100 |
| Uniprot #: | SwissProt: O14733 Human | Q8CE90 Mousen | Q4KSH7 Rat |
| Alternative names: | c-Jun N-terminal kinase kinase 2 Dual specificity mitogen activated protein kinase kinase 7 Dual specificity mitogen-activated protein kinase kinase 7 JNK activating kinase 2 JNK kinase 2 JNK-activating kinase 2 JNKK 2 Jnkk-2 Jnkk2 MAP kinase kinase 7 MAP2K7 MAPK/ERK kinase 7 MAPKK 7 MAPKK-7 MAPKK7 MEK 7 Mitogen Activated Protein Kinase kinase 7 MKK 7 MKK-7 MKK7 MP2K7_HUMAN PRKMK 7 PRKMK-7 PRKMK7 SAPK kinase 4 SAPKK-4 SAPKK4 Sek 2 Sek-2 Sek2 SKK4 stress-activated protein kinase kinase 4 |
Images
|
Fig1:
Western blot analysis of MEK7 on different lysates with Rabbit anti-MEK7 antibody (ET1612-35) at 1/1,000 dilution. Lane 1: HeLa (Human cervical adenocarcinoma cell) cell lysate Lane 2: 293T (Human embryonic kidney cell) cell lysate Lane 3: A431 (Human epidermoid carcinoma skin squamous cell) cell lysate Lane 4: Caco-2 (Human colorectal adenocarcinoma cell) cell lysate Lane 5: A549 (Human lung adenocarcinoma cell) cell lysate Lysates/proteins at 20 µg/Lane. Exposure time: 8 seconds; ECL: K1801 Blocking: 5% NFDM/TBST, 1 hour at room temperature Primary antibody: ET1612-35, 1/1,000 in 5% NFDM/TBST, overnight at 4 ℃ Secondary antibody: Goat anti-Rabbit IgG-HRP (HA1001), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature Predicted band size: 47 kDa Observed band size: 47 kDa |
|
Fig2:
Western blot analysis of MEK7 on different lysates with Rabbit anti-MEK7 antibody (ET1612-35) at 1/1,000 dilution. Lane 1: A549-WT cell lysate Lane 2: A549-KD MEK7 cell lysate Lysates/proteins at 10 µg/Lane. Predicted band size: 47 kDa Observed band size: 47 kDa Exposure time: 3 minutes; ECL: K1801; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (ET1612-35) at 1/1,000 dilution was used in 2% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature. |
|
Fig3: ICC staining MEK7 in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS. |
|
Fig4: ICC staining MEK7 in SHG-44 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS. |
|
Fig5: ICC staining MEK7 in SH-SY-5Y cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS. |
|
Fig6: Immunohistochemical analysis of paraffin-embedded rat bladder tissue using anti-MEK7 antibody. Counter stained with hematoxylin. |
|
Fig7: Immunohistochemical analysis of paraffin-embedded mouse bladder tissue using anti-MEK7 antibody. Counter stained with hematoxylin. |
|
Fig8: Immunohistochemical analysis of paraffin-embedded rat brain tissue using anti-MEK7 antibody. Counter stained with hematoxylin. |
Note: All products are “FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE”.